Langlui's Big Board and Options Plays

[jaybird249]

May 20 presentation: AGEN Cancer Vaccine 3 X better than DNDN
http://www.chasingthealpha.com/2010/05/agen-some-undiscovered-news-about-data.html
AGEN will release a PR this week on May 20 presentation. The results are amazing.
Results: HSp vaccine was well tolerated with no serious adverse events attributable to vaccine and no related grade 3 or 4 toxicities. In patients with recurrent GBM (n=32) the overall median survival approximated 44 weeks post-resection and the majority (94%) of patients survived beyond the historical median of 26-weeks.

****Approximately 70% of patients survived beyond 36 weeks and 41% survived up to or longer than 1-year.*****

All patients with immunological endpoints tested to date exhibited a significant innate immune response following vaccine administration and 92% of patients demonstrated CD8 T cell IFN gamma production upon restimulation with recombinant gp-96 (p<0.01). The majority of patients (92%) exhibited significant Th1 type responses as measured by multi-cytokine qpCR. The presence of an adaptive immune response and minimal residual disease was associated with survival beyond 36 weeks. In patients with newly diagnosed GBM (n=8; trial initiated 2009), there have been no significant toxicities associated with concurrent treatment of HSppC-96 and temozolomide. Clinical and immunologic evaluation is ongoing.

In contrast with DNDN and Provenge only increased survival by only 23% for prostate cancer. This is a huge victory for AGEN and shareholders. Historically, recurrent glioblastoma multiforme has a median survival of three to six months. 70% INCREASE IN SURVIVAL.